152,771 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 152,771 shares of Protagonist Therapeutics during the first quarter, valued at approximately $7.39 million, bringing their ownership to 0.25% of the company.
• Protagonist Therapeutics recently reported an EPS of ($0.55) for the quarter, missing analysts' expectations and generating $5.55 million in revenue, below the forecast of $8.32 million.
• Several institutional investors have increased their stakes in Protagonist Therapeutics, leading to a significant overall ownership of 98.63% by institutional investors.

Nuveen LLC bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 152,771 shares of the company's stock, valued at approximately $7,388,000. Nuveen LLC owned about 0.25% of Protagonist Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Protagonist Therapeutics during the fourth quarter valued at $48,000. GAMMA Investing LLC grew its position in shares of Protagonist Therapeutics by 153.3% during the first quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after acquiring an additional 728 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Protagonist Therapeutics by 38.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,992 shares of the company's stock worth $96,000 after acquiring an additional 551 shares during the last quarter. Covestor Ltd grew its position in shares of Protagonist Therapeutics by 27.0% during the first quarter. Covestor Ltd now owns 2,087 shares of the company's stock worth $101,000 after acquiring an additional 444 shares during the last quarter. Finally, Penserra Capital Management LLC bought a new position in shares of Protagonist Therapeutics during the first quarter worth about $117,000. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX traded up $0.70 on Friday, reaching $58.84. The company's stock had a trading volume of 362,541 shares, compared to its average volume of 922,678. Protagonist Therapeutics, Inc. has a twelve month low of $33.31 and a twelve month high of $61.89. The stock has a market cap of $3.66 billion, a PE ratio of 84.05 and a beta of 2.33. The firm's 50 day moving average is $54.47 and its two-hundred day moving average is $49.08.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The business had revenue of $5.55 million during the quarter, compared to analyst estimates of $8.32 million. Equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PTGX has been the subject of several recent research reports. JMP Securities upped their price target on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the stock a "market outperform" rating in a research report on Thursday, August 7th. Citigroup reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. Finally, Wall Street Zen raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $67.20.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $54.78, for a total transaction of $570,533.70. Following the completion of the sale, the chief executive officer directly owned 520,603 shares of the company's stock, valued at approximately $28,518,632.34. This represents a 1.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arturo Md Molina sold 10,000 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total transaction of $570,300.00. Following the sale, the insider directly owned 83,892 shares of the company's stock, valued at approximately $4,784,360.76. This represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,859 shares of company stock valued at $4,020,877. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.